Quinidine, disopyramide, procainamide, solatol, amiodarone, bepridil, Cisapride, sultopride,thioridazine,

Intravenous erythromycin, intra veous vincamine, Halofanthine, pentamidine, spafloxacin,

Ditiazem, betablockers, verapramil, clonidine, digoxin, Hypokalemic agents, diuretics, stimulant laxatives,

I V amphotericin, glucocorticoids,

Other antipschyotic CNS depressants ( including alcohol )

Neuroleptics, and other drugs that could induce torsades de points, Levodopa, antihypertensives

Insomnia, anxiety, agitaion, somnolence GI upse, raised serum prolactin,

Weight gain, dystonia, extrapyrimidal reactions, tardive dyskinea, Amenorrhea, impotence,

Hypotension,bradycardia,

QT prolongation, Torsesades de Pointes

Allergic reactions, Risk of neuroleptic malignant syndrome

Withdraw if hyperthermia occurs

Protein -dependent tumours, phaetocromocytoma

Concomittant Class IA III antiarrhythmics ( eg quinidine, disopyramide, amiodarone, solatol )

Others which increase risk of Torsedes de Pointes including ( eg cisapride, iv erthromycin, pentamide ) levodopa

Special precaution-

Bradycardia, hypokalemia

QT prolongation, renal impairment, epilepsy

Parkinsons disease

Elderly, withdraw gradually

Hepatic impairment

Lactation,

Pregnancy

Contraception must be used

Date of Approval       2006

Indication-

Schizophrenia

Dosage

Acute episode - initially 400-800mg daily in 2 divided doses

Adjust according to response

Mixed symptoms - adjust dose to control positive symptoms

Predominent negative symptoms- 50 - 300mg daily as a single dose

Not recommended for children

Preferably taken before meals

Preferably taken before meals

Contraindicated for use during pregnanncy and lactation

Caution should be excercised if required to be used